These results demonstrate that antisense-mediated suppression of tau protein synthesis in the CNS of participants with mild AD is possible and warrant further evaluation of the effect of MAPTRx on the clinical course of patients with AD and in other tauopathies. The gene discussed is MAPT; the disease is Alzheimer disease.